Compare Enveric Biosciences Inc (ENVB) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Yum! Brands, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Yum! Brands, Inc. trades at $145.4 (market cap $39.66B). The key difference: Yum! Brands, Inc. is far larger — about 6396.8× Enveric Biosciences Inc's market cap, and Yum! Brands, Inc. pays a 2.06% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | YUM | |
|---|---|---|
Market Cap | $6.20M | $39.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $168.16 |
52-Week Low | $1.27 | $138.21 |
Enterprise Value | $1.30M | $51.26B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
YUM trades at $150.76, down 0.95% on the day, amid a bearish technical signal and recent sales headwinds from a parasite outbreak affecting Taco Bell. The company reported Q2 2026 EPS of $1.62, beating estimates, and completed the $1.2 billion sale of Pizza Hut China. Revenue growth is steady, with 2025 revenue at $8.21 billion and net income margin of 25.4%, though debt remains elevated. Analyst consensus is a Buy with a $174.60 price target, but legal investigations and food safety concerns present near-term risks.
The outlook is mixed: strong digital growth and portfolio streamlining offer upside, but the stock faces pressure from the cyclospora outbreak's impact on sales and ongoing fraud probes. Investors should weigh solid fundamentals against sentiment-driven volatility and high leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
